
This analysis in RR MCL shows CAR T-cell therapy (brexucabtagene) yields higher complete responses vs bispecific antibodies; durability remains unclear.
Supplements and Featured Publications
almost 30 years ago
MCO Decisions and Solutionsalmost 30 years ago
The Importance of Lipid Lowering and Other Risk Reduction Therapiesalmost 30 years ago
Matching Risks to Interventions: When to Treat, How to Treatalmost 30 years ago
CME Quizalmost 30 years ago
Bibliographyalmost 30 years ago
Participantsalmost 30 years ago
Goals and Objectivesalmost 30 years ago
Introductionalmost 30 years ago
Clinical Study Outcomes and the Benefits of Treating Hypercholesterolemiaalmost 30 years ago
Goals for Patient Treatment





